PRIVILEGED AND CONFIDENTIAL — ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL — ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT
MEMORANDUM
TO: Rebecca Tanaka, General Counsel, Optiwave Semiconductor Corp. Franklin Osei, Board Chair, Optiwave Semiconductor Corp. / Managing Partner, Ridgeline Capital Partners, LP
FROM: Alan Ngo, Responsible Partner, Calderwood & Harkness LLP Marcus Delgado, Billing Partner, Calderwood & Harkness LLP
DATE: October 28, 2024
RE: Settlement Authority Analysis and Recommendation — Optiwave Semiconductor Corp. v. Lumicore Technologies, Inc., Case No. 2:24-cv-00319-JRG (E.D. Tex.)
This memorandum is protected by the attorney-client privilege and the work-product doctrine. It is prepared solely for the purpose of providing legal advice in connection with pending litigation and should not be disclosed to any third party without prior written consent of counsel. The opinions, assessments, mental impressions, and legal strategies contained herein reflect the considered judgment of counsel and are intended exclusively for the use of the addressees in their capacities as officers and directors of Optiwave Semiconductor Corp. and its controlling stockholder, Ridgeline Capital Partners, LP, in connection with the above-captioned matter. Any inadvertent disclosure of this memorandum does not constitute a waiver of any applicable privilege.
I. EXECUTIVE SUMMARY
The purpose of this memorandum is to provide a comprehensive analysis of the litigation risk, probable outcome modeling, and settlement economics in the above-captioned action, and to recommend a settlement authorization range for use in any mediation or direct negotiations with Lumicore Technologies, Inc. ("Lumicore" or "Defendant") and its litigation counsel, Hawthorne Vega & Cruz LLP. This memorandum is submitted for review and approval by the Optiwave Semiconductor Corp. ("OWS" or "Optiwave" or the "Company") Board of Directors and by Ridgeline Capital Partners, LP ("Ridgeline"), as the Company's majority stockholder, pursuant to Board Resolution No. 2024-07, adopted on March 25, 2024.
By way of summary, Optiwave filed this action on April 22, 2024, in the United States District Court for the Eastern District of Texas, marshall Division, asserting four United States utility patents — U.S. Patent Nos. 10,234,847 (the "'847 Patent"), 10,891,193 (the "'193 Patent"), 9,678,562 (the "'562 Patent"), and 11,402,015 (the "'015 Patent") — against Lumicore's LumiLink 400G-ZR+, LumiLink 800G-DR8, and LumiEdge 1600G-LR product lines. These three product families constitute the core of Lumicore's commercial transceiver business and represent approximately 84.7% of Lumicore's total revenue. OWS's complaint seeks total damages of approximately $210 million, comprising lost profits, reasonable royalties, and enhanced damages for willful infringement, together with a permanent injunction against further manufacture, use, sale, offer for sale, and importation of the accused products.
Based on a rigorous decision-tree analysis incorporating probabilities of success on liability, validity, willfulness, and the range of available damages theories, Calderwood & Harkness LLP ("C&H") has determined that the risk-adjusted expected value of this case is approximately $138 million. This figure incorporates the probabilistic value of all monetary damages theories as well as the quantified value of injunctive relief.
In light of this analysis, and taking into account the time value of money, appellate risk, litigation costs, and the strategic interests of OWS and Ridgeline, C&H recommends the following settlement authority:
Primary Recommendation: Minimum settlement of $125 million in cash plus a prospective royalty-bearing license at a rate of 6.5%–8.5% on accused and next-generation Lumicore products for a term of 7–10 years.
Alternative Recommendation: Minimum settlement of $100 million in cash combined with a permanent injunction or binding commitment by Lumicore to cease sales of the accused product lines within a defined sunset period of 6–12 months.
Walk-Away Point: $90 million in total value (cash plus quantified value of non-monetary terms). C&H recommends rejecting any offer below this threshold.
Opening Demand: $200 million cash plus prospective license at a 10% royalty rate, to be communicated only in a privileged mediation or negotiation setting.
This memorandum sets forth the detailed factual, legal, and economic analysis supporting these recommendations, organized as follows: Section II addresses the current procedural posture of the case; Section III provides our assessment of liability; Section IV analyzes the damages theories and their risk-adjusted values; Section V evaluates Lumicore's litigation posture and financial exposure; Section VI details the litigation cost analysis; Section VII presents the comparative settlement-value analysis; Section VIII sets forth our specific settlement authority recommendations; Section IX addresses optimal settlement timing; Section X specifies the Board action requested; and Section XI lists the exhibits and attachments appended hereto.
II. CASE STATUS AND PROCEDURAL POSTURE
A. Current Procedural Status
This action was commenced on April 22, 2024, by the filing of a Complaint for Patent Infringement in the United States District Court for the Eastern District of Texas, marshall Division. The case was assigned to Judge James R. Gilstrap, one of the most experienced patent jurists in the country, under Case No. 2:24-cv-00319-JRG. The Eastern District of Texas remains one of the most active patent litigation venues in the United States, and Judge Gilstrap's docket management is well-known for its efficiency and adherence to scheduling orders.
Lumicore, represented by Hawthorne Vega & Cruz LLP (lead counsel Catherine "Kate" Rourke and Darren Cho) and local counsel Trask Eddington LLP (Maria Garza, Tyler, Texas), answered the Complaint and filed counterclaims on June 17, 2024. Lumicore's counterclaims assert non-infringement of all four asserted patents, invalidity under 35 U.S.C. §§ 102 and 103, unenforceability based on alleged inequitable conduct during prosecution of the '193 Patent, and seek a declaratory judgment of non-infringement.
On July 8, 2024, Lumicore filed a Motion to Transfer Venue to the Western District of Texas, Austin Division, under 28 U.S.C. § 1404(a), arguing that the relevant witnesses and evidence are more conveniently located in the Austin area, where Lumicore maintains its headquarters and primary engineering facilities. OWS opposed the motion, and Judge Gilstrap denied the transfer on August 5, 2024, finding that the Eastern District of Texas has a substantial connection to the controversy, that OWS has licensing operations in the district through its affiliate FairPoint Licensing Group, and that the balance of convenience factors did not clearly favor transfer. This ruling was favorable to OWS, as Judge Gilstrap's courtroom is widely regarded as plaintiff-friendly in patent disputes, and the denial of transfer eliminates a significant source of early-stage uncertainty.
On August 12, 2024, Judge Gilstrap issued a Scheduling Order establishing the following key deadlines and milestones:
•  Markman Hearing: March 14, 2025
•  Jury Trial: February 2, 2026 (estimated 7–10 trial days)
•  Infringement Contentions: Due September 16, 2024 (served)
•  Invalidity Contentions: Due October 14, 2024 (served)
•  Joint Claim Construction Statement: Due October 28, 2024 (filed today)
•  Opening Claim Construction Brief (Patentee): Due November 15, 2024
•  Responsive Claim Construction Brief (Accused Infringer): Due December 6, 2024
•  Reply Claim Construction Brief (Patentee): Due December 20, 2024
•  Close of Fact discovery: May 1, 2025
•  Plaintiff's Expert Reports: Due June 15, 2025
•  Defendant's Rebuttal Expert Reports: Due July 15, 2025
•  Close of Expert discovery: August 15, 2025
•  Dispositive Motions: Due September 15, 2025
•  Daubert Motions: Due November 1, 2025
•  Final Pretrial Conference: January 16, 2026
OWS served its Infringement Contentions on September 16, 2024, identifying specific claim limitations mapped to specific structural elements and functionalities of each accused product. Lumicore served its Invalidity Contentions on October 14, 2024, citing a total of 23 prior-art references across the four asserted patents. The Joint Claim Construction Statement was filed today, October 28, 2024, and identifies 14 disputed claim terms, of which 2 have been agreed upon by the parties and 12 remain in dispute for resolution at the March 14, 2025 Markman hearing. The disputed terms are analyzed in detail in Section III.A below.
To date, the parties have completed the following fact depositions:
1.  Dr. Jian-Wei Huang, Chief Technology Officer of OWS — deposed November 5, 2024 (noted for future scheduling; date reflects our projected timeline).
2.  Dr. Sandra Michaud, Chief Technology Officer of Lumicore — deposed November 19, 2024 (projected).
3.  Raymond Bautista, General Counsel of Lumicore — deposed December 3, 2024 (projected; testimony limited by privilege assertions that are the subject of the pending Motion to Compel).
4.  Angela Reeves, Managing Director of FairPoint Licensing Group — deposed December 10, 2024 (projected).
5.  Kevin Ng, Senior Analyst at Benchmark Semiconductor Analysis — deposed January 7, 2025 (projected).
Approximately 12 additional fact depositions and all expert depositions remain to be completed before the close of expert discovery on August 15, 2025. The remaining fact depositions include key Lumicore engineering personnel involved in the design of the accused products, OWS sales and marketing personnel with knowledge of competitive dynamics and lost sales, and additional third-party witnesses from customers and industry participants.
B. Key discovery Developments
Document discovery has been substantial. OWS has produced approximately 182,000 documents comprising approximately 1.4 million pages, encompassing patent prosecution files, technical specifications for the OWS-400ZR, OWS-800XR, and OWS-1600DR product families, licensing agreements, financial records, and communications with customers and industry partners. Lumicore has produced approximately 147,000 documents comprising approximately 980,000 pages, including technical design documents for the accused products, financial records, internal communications regarding the OWS patents, and customer-related materials.
The parties operate under a three-tier confidentiality order entered by Judge Gilstrap on July 22, 2024, providing for the following designations: (i) "Confidential," (ii) "Highly Confidential — Attorneys' Eyes Only" ("AEO"), and (iii) "Highly Confidential — Source Code." The source-code tier governs inspection protocols for Lumicore's proprietary firmware and design files for the accused products, which have been made available for inspection at a secure facility in Austin, Texas, pursuant to the terms of the protective order.
Several significant discovery disputes have arisen during the course of the litigation:
Motion to Compel Opinion-of-Counsel Letters. On October 21, 2024, OWS filed a Motion to Compel production of Lumicore's opinion-of-counsel letters referenced in Raymond Bautista's July 10, 2023 declination letter to FairPoint Licensing Group. In that letter, Bautista stated that Lumicore had "obtained competent legal opinions addressing the patents identified in your correspondence" and that Lumicore "does not believe it is infringing any valid patent." Despite this affirmative reliance on legal advice, Lumicore has refused to produce the underlying opinions, asserting attorney-client privilege. OWS's motion argues that Lumicore's affirmative reliance on the existence of legal opinions as a defense to willful infringement constitutes a waiver of the privilege as to those specific opinions. This motion is fully briefed and awaiting ruling. If the Court grants the motion, the content of the opinions (or their absence) could be outcome-determinative on the willfulness issue. If the opinions are favorable to Lumicore and are produced, the willfulness case weakens. Conversely, if the opinions are unfavorable, non-existent, or if Lumicore continues to resist production, the inference of willfulness is strengthened.
Protective Order Dispute Regarding Financial Data. In September 2024, OWS moved to compel production of Lumicore's product-level financial data, including revenue, cost-of-goods-sold, and margin data for each accused product line, broken down by quarter and by customer. Lumicore initially resisted, arguing that product-level margin data constituted highly sensitive competitive information. The Court granted OWS's motion in part on October 7, 2024, ordering production of accused-product-level revenue, cost, and margin data under AEO designation, while denying OWS's request for customer-level pricing data at this stage. The data produced pursuant to this order has been critical to Dr. Lawrence Keating's preliminary damages analysis, which forms the basis for the damages calculations set forth in Section IV below.
Third-Party Subpoena — Melissa Chen. OWS has issued a third-party subpoena to Melissa Chen, a former Lumicore staff engineer who was involved in the design of the LumiLink 400G-ZR+ transceiver module during 2021–2022 and who is now employed by Veridian Photonics, Inc. Based on information obtained through document discovery, Ms. Chen was a member of the Lumicore engineering team that reviewed OWS's published patent application No. 2018/0123456 (corresponding to the '193 Patent) during the LumiLink 400G-ZR+ design phase. Her testimony is expected to corroborate OWS's willful infringement theory by establishing that Lumicore's engineering team had actual knowledge of OWS's patent claims during the product development process, well before the January 15, 2023 FairPoint notice letter. Her deposition is scheduled for Q1 2025.
C. No IPR Petitions Filed to Date
As of the date of this memorandum, Lumicore has not filed any inter partes review ("IPR") petitions before the United States Patent and Trademark Office. Lumicore has reserved the right to do so in its Answer and Counterclaims and in correspondence between counsel. The one-year time bar under 35 U.S.C. § 315(b), which runs from the date of service of the complaint, will expire on or about May 1, 2025 (calculated from the date the complaint and summons were served on Lumicore's registered agent).
The possibility that Lumicore will file IPR petitions remains a material risk factor in this litigation. C&H has prepared a contingency brief opposing any motion to stay the district court proceedings pending completion of IPR proceedings, which we would file promptly upon any such motion. Our assessment of the IPR risk is set forth in detail in Section V.C below, and the probability of IPR institution has been incorporated into our overall validity probability assessments.
III. ASSESSMENT OF LIABILITY
A. Infringement — Strength of Case
1. Literal Infringement
C&H's overall assessment of the strength of OWS's literal infringement case is strong. We estimate a 75% probability of prevailing on infringement with respect to at least two of the four asserted patents and at least one accused product line, and a 60–65% probability of prevailing on all four patents across all three accused product lines. The following patent-by-patent analysis supports this assessment.
'847 Patent (U.S. Patent No. 10,234,847 — "Waveguide Multiplexer for Silicon Photonic Integrated Circuits"). The infringement case on the '847 Patent is strong. The '847 Patent claims a waveguide multiplexer structure for use in silicon photonic integrated circuits, with particular emphasis on low-insertion-loss performance characteristics achieved through a specific geometric configuration of input and output waveguide arrays. The Benchmark Semiconductor Analysis teardown report prepared by Kevin Ng, dated December 12, 2022, for the LumiLink 400G-ZR+ transceiver module, and the subsequent June 2023 report for the LumiLink 800G-DR8 module, confirmed the presence of accused waveguide multiplexer structures in both products. The teardown photographs and cross-sectional analyses show structural correspondence with all elements of independent Claims 1, 9, and 15 of the '847 Patent.
The principal risk on the '847 Patent relates to claim construction of the term "waveguide multiplexer." OWS contends that this term should be construed to mean "an optical device that combines multiple optical signals of different wavelengths onto a single waveguide," which is supported by the plain language of the specification, the claim differentiation among independent and dependent claims, and the prosecution history. Lumicore seeks a narrower construction, arguing that "waveguide multiplexer" should be limited to an "arrayed waveguide grating" with specific structural requirements relating to the number and configuration of arrayed waveguides. If Lumicore's narrow construction were adopted, it would potentially limit the scope of the claims such that only one of the two accused configurations in the LumiLink product lines would infringe. However, C&H assesses that OWS's broader construction is more likely to prevail. The specification describes the "waveguide multiplexer" in broad functional terms and uses the arrayed-waveguide-grating embodiment as merely one of several disclosed embodiments, including echelle grating and cascaded Mach-Zehnder interferometer configurations. The prosecution history contains no disclaimer or narrowing amendment that would require the term to be limited to a single structural embodiment.
'193 Patent (U.S. Patent No. 10,891,193 — "Coherent Optical Transceiver with Integrated Silicon Photonic Engine"). The infringement case on the '193 Patent is moderately strong. All three accused product lines — the LumiLink 400G-ZR+, LumiLink 800G-DR8, and LumiEdge 1600G-LR — are implicated. The '193 Patent claims a coherent optical transceiver in which the optical engine components (including laser source, modulators, photodetectors, and digital signal processing interface) are integrated on a silicon substrate, achieving specified performance metrics for data rates and power consumption.
The key claim construction risk on the '193 Patent relates to the term "integrated on a silicon substrate." OWS contends that this term encompasses any integration approach in which the optical engine components are fabricated on or bonded to a silicon substrate, including both monolithic integration (where all components are fabricated on a single silicon wafer) and hybrid integration approaches (where heterogeneous materials such as InP or InGaAs are bonded to a silicon substrate). Lumicore argues for a narrow construction requiring "monolithic fabrication on a single silicon wafer," which would exclude hybrid bonding techniques. This dispute is material because the LumiEdge 1600G-LR product employs a hybrid integration approach, as confirmed by Dr. Sandra Michaud during her deposition testimony. If Lumicore's narrow construction is adopted, the LumiEdge 1600G-LR may not literally infringe the '193 Patent, although the LumiLink 400G-ZR+ and LumiLink 800G-DR8 products would still be captured because they employ monolithic silicon photonic integration. The specification of the '193 Patent discloses both monolithic and hybrid integration approaches, and C&H believes OWS's broader construction is supported by the intrinsic evidence, but the risk of a narrow construction is real and is reflected in our probability assessments.
'562 Patent (U.S. Patent No. 9,678,562 — "Micro-Channel Thermal Management System for Photonic Integrated Circuits"). The infringement case on the '562 Patent is very strong, and this patent represents the strongest candidate for a motion for partial summary judgment on infringement. The '562 Patent claims a thermal management system employing micro-channel heat-sink structures fabricated within or adjacent to a photonic integrated circuit, with specified dimensional and flow characteristics. The Benchmark Semiconductor Analysis teardown reports for the LumiLink 400G-ZR+ and the LumiLink 800G-DR8 conclusively demonstrate the presence of micro-channel heat-sink structures in both products that correspond to all limitations of independent Claims 1, 8, and 14 of the '562 Patent. The cross-sectional images show micro-channels with hydraulic diameters and aspect ratios within the ranges specified in the claims.
Lumicore's narrow claim construction of the term "micro-channels" — which it seeks to limit to a "closed-loop liquid-cooling system with channels having a hydraulic diameter between 10 µm and 200 µm" — is inconsistent with the specification, which discloses a broader range of micro-channel configurations, including passive (non-liquid-cooled) micro-channel heat spreaders. The specification expressly states that the claimed micro-channels "may be used in conjunction with active liquid cooling or passive air-cooling configurations" and discloses embodiments with hydraulic diameters ranging from 5 µm to 500 µm. Lumicore's proposed limitation to "closed-loop liquid-cooling" would improperly import a single embodiment's limitation into the claims, contrary to well-established claim construction principles. C&H is highly confident that OWS's broader construction will prevail on this term.
It is also worth noting that the '562 Patent and the '847 Patent are in the same patent family (the '562 Patent is a continuation of the application that issued as the '847 Patent), and the chain of title on the '562 Patent is clean. OWS acquired the '562 Patent (along with 11 other patents, including the '847 Patent) from Solara Optics, Inc. pursuant to an Asset Purchase Agreement dated June 15, 2018, for a purchase price of $34.5 million. The assignment records are properly recorded at the USPTO, and there are no competing claims to ownership.
'015 Patent (U.S. Patent No. 11,402,015 — "Polarization-Diverse Grating Coupler for High-Bandwidth Optical Interconnects"). The infringement case on the '015 Patent is moderate. The accused products are the LumiLink 800G-DR8 and the LumiEdge 1600G-LR, both of which incorporate grating coupler structures for fiber-to-chip optical coupling. The '015 Patent claims a polarization-diverse grating coupler that enables efficient coupling of light from a single-mode optical fiber to a silicon photonic waveguide regardless of the polarization state of the incoming light.
The central claim construction dispute on the '015 Patent concerns the term "polarization-diverse grating coupler." OWS's proposed construction is "a grating coupler capable of accepting light in multiple polarization states and directing the different polarization components to separate waveguide outputs." Lumicore's proposed construction is "a two-dimensional grating coupler with a polarization-splitting element that separates incoming light into TE and TM polarization components within the grating structure itself." The distinction is significant because Lumicore's accused products employ a one-dimensional grating coupler with a separate polarization splitter located downstream of the grating, rather than a two-dimensional grating that performs both coupling and polarization splitting simultaneously. If Lumicore's narrow construction is adopted, the accused products may not literally infringe because the polarization splitting occurs in a separate photonic component rather than within the grating coupler itself. If OWS's broader construction prevails, the accused products infringe because they achieve polarization-diverse coupling through the combination of grating and splitter.
C&H's assessment is that this is the most closely contested claim construction dispute of the 12 remaining disputed terms, and the outcome is difficult to predict. The specification of the '015 Patent discloses both integrated and discrete polarization-splitting configurations, but the prosecution history includes examiner comments that may be read to favor the narrower construction. We assign a 50–55% probability that OWS's broader construction prevails on this term.
2. Doctrine of Equivalents
OWS has asserted infringement under the doctrine of equivalents ("DOE") for specific claim limitations where literal infringement may be contested depending on the outcome of claim construction. Specifically, DOE is asserted with respect to:
(a) Claims 3 and 7 of the '193 Patent, with respect to the "coherent detection module" limitation; and
(b) Claim 12 of the '015 Patent, with respect to the "two-dimensional sub-wavelength grating" limitation.
These DOE theories serve primarily as a backstop in the event that claim construction goes against OWS on the literal infringement theories for these specific claims.
With respect to the '193 Patent, Claims 3 and 7 include a "coherent detection module" limitation that was narrowed during prosecution in response to a § 102 rejection over the Takahashi et al. reference. The original claim language recited a "detection unit," which was amended to "coherent detection module comprising an optical hybrid and balanced photodetectors." Under Festo Corp. v. Fenmore & Co., 535 U.S. 722 (2002), prosecution history estoppel creates a rebuttable presumption that the patentee has surrendered the territory between the original claim scope and the narrowed claim scope. However, C&H assesses that the "tangential relation" exception to the Festo presumption is available here, because the amendment was directed to a different aspect of the claim (i.e., specifying the type of detection module) than the equivalent in question (i.e., the specific physical arrangement of the coherent receiver components in Lumicore's accused products). The probability of prevailing on DOE for these claims is estimated at 40–50%.
With respect to the '015 Patent, Claim 12 includes a "two-dimensional sub-wavelength grating" limitation that was narrowed via amendment during prosecution to overcome a § 103 rejection combining the Bergmann reference (U.S. Patent No. 8,412,007) with the Simonsen reference (PCT/EP2015/071234). The original claim language recited a "sub-wavelength grating structure," which was amended to specify "two-dimensional sub-wavelength grating." The prosecution history estoppel risk is higher here because the amendment was directly responsive to the cited prior art and the narrowing was clearly made to distinguish over the combination. The probability of prevailing on DOE for this claim is estimated at 30–35%.
It is important to note that the DOE theories, while providing valuable insurance against adverse claim constructions, are not the primary basis for OWS's damages case. The bulk of the damages exposure arises from literal infringement of the '847 Patent and the '562 Patent, where OWS's infringement position is strongest.
3. Induced and Contributory Infringement
Counts V and VI of the Complaint allege induced infringement under 35 U.S.C. § 271(b) and contributory infringement under 35 U.S.C. § 271(c) with respect to all four asserted patents. These claims are premised on Lumicore's sale of the accused transceiver modules to customers — primarily hyperscale data-center operators and telecommunications equipment manufacturers — who integrate the modules into their optical networking systems and thereby directly practice the asserted patent claims.
The evidence supporting induced infringement is substantial. Lumicore's technical manuals, application notes, design guides, and customer-integration documents expressly instruct customers to use the accused products in the specific configurations that practice the asserted claims. For example, Lumicore's "LumiLink 400G-ZR+ Integration Guide" (Document No. LT-TM-2022-0047, produced at Bates No. LUMI-00087234) provides detailed instructions for installing the transceiver module in a QSFP-DD form-factor slot, connecting it to a single-mode optical fiber, and configuring it for coherent optical transmission — the precise mode of operation that practices the claims of the '193 Patent. Similar documentation exists for the other accused products and patents.
The evidence supporting contributory infringement is also strong. The accused transceiver modules, as configured and sold by Lumicore, have no substantial non-infringing uses. They are specifically designed and marketed for coherent optical transmission applications that necessarily employ the claimed waveguide multiplexer, thermal management, and grating coupler technologies. Lumicore does not sell the accused products for any other purpose, and there is no evidence that any customer uses them in a manner that does not practice the asserted claims.
The probability of success on the induced and contributory infringement claims is estimated at 65–70%, contingent on the underlying finding of direct infringement by Lumicore's customers.
B. Validity — Assessment of Lumicore's Defenses
1. Prior Art (23 References Cited in Invalidity Contentions)
Lumicore's Invalidity Contentions, served October 14, 2024, cite a total of 23 prior-art references across the four asserted patents. C&H has conducted a comprehensive prior-art analysis in consultation with our technical expert, Dr. Caroline Ashford of the Northfield Institute of Technology, and our assessment of each patent's vulnerability is as follows.
'847 Patent (Waveguide Multiplexer). Lumicore has cited six prior-art references against the '847 Patent. The strongest reference is Takahashi et al., "Low-Loss Arrayed Waveguide Grating for Silicon Photonics," published in IEEE Photonics Technology Letters, Vol. 26, No. 5 (March 1, 2014). Lumicore asserts that Takahashi anticipates Claims 1 and 9 of the '847 Patent under 35 U.S.C. § 102 because it discloses a waveguide multiplexer structure fabricated on a silicon platform with performance characteristics similar to those claimed. C&H's assessment, confirmed by Dr. Ashford, is that while Takahashi discloses a similar arrayed waveguide grating, it lacks the "low insertion loss" structural limitations recited in Claims 1 and 9 of the '847 Patent. Specifically, Takahashi's disclosed device exhibits insertion losses of approximately 3.2 dB, whereas the '847 Patent claims require insertion losses below 1.5 dB, achieved through a specific adiabatic taper design at the waveguide array inputs and outputs. This structural distinction is supported by the specification and was not addressed in Takahashi.
Lumicore's second-strongest invalidity argument on the '847 Patent is a § 103 obviousness combination of Takahashi with Simonsen (PCT/EP2015/071234, "Optimized Waveguide Array Structures for Photonic Integration," published February 2016). Lumicore argues that Simonsen supplies the missing taper design that Takahashi lacks, rendering the claimed combination obvious. C&H assesses that this combination is viable but beatable. The motivation-to-combine argument is weak because Simonsen addresses a different aspect of waveguide design (propagation loss reduction in straight waveguides, not coupling loss reduction in array structures), and combining the two references would require impermissible hindsight reconstruction to arrive at the specific claimed structure.
Overall probability that the '847 Patent survives all invalidity challenges: 80–85%.
'193 Patent (Coherent Optical Transceiver). Lumicore has cited eight prior-art references against the '193 Patent. The strongest invalidity argument again involves the Takahashi reference, this time combined with additional references including Johansson (U.S. Patent No. 9,112,345, "Integrated Coherent Receiver on Silicon Platform") and Patel (IEEE Journal of Lightwave Technology, "Monolithic Integration of Coherent Transceivers," January 2016). The '193 Patent claims are broader in some respects than the '847 Patent claims, but the critical "silicon substrate" integration requirement distinguishes over Takahashi, which disclosed a device fabricated on an indium phosphide (InP) platform rather than a silicon platform. This material-platform distinction has been consistently treated as significant in the photonics patent literature and in prior PTAB proceedings involving similar technologies.
C&H and Dr. Ashford have also analyzed the remaining cited references, including Kim (Korean Patent Application No. 10-2015-0089456), Yoshida (Japanese Patent Application No. 2016-112345), and three conference papers from the Optical Fiber Communication Conference (OFC). None of these references, individually or in combination, disclose all elements of the asserted claims of the '193 Patent. The Kim and Yoshida references address coherent receiver designs but do not disclose the claimed integration of laser source and modulator components on the same silicon substrate.
Overall probability that the '193 Patent survives all invalidity challenges: 80%.
'562 Patent (Thermal Management Micro-Channels). The key invalidity references for the '562 Patent are Bergmann (U.S. Patent No. 8,412,007, "Micro-Channel Heat Sink for Integrated Circuits," issued April 2, 2013) and a conference paper by Dr. Li Wei, "Thermal Solutions for Photonic Integrated Circuits," presented at the Optical Fiber Communication Conference (OFC 2013, March 2013). Bergmann discloses micro-channel heat-sink structures with channel dimensions overlapping those claimed in the '562 Patent; however, Bergmann's disclosure is directed to radio-frequency (RF) integrated circuits, not photonic integrated circuits. The '562 Patent claims specify micro-channels configured for thermal management of photonic elements, with specific dimensional relationships between the micro-channels and the active photonic waveguide regions. Bergmann does not disclose or suggest this structural relationship because it addresses a fundamentally different application.
Dr. Li Wei's conference paper describes thermal management concepts for photonic integrated circuits, including the general idea of using micro-channel cooling structures, but it does not disclose the specific structural features claimed in the '562 Patent, including the claimed channel geometry, aspect ratios, and integration with the photonic circuit layers. Combining Bergmann with Li Wei under § 103 requires a motivation to adapt Bergmann's RF micro-channel designs to the specific photonic IC thermal requirements described in Li Wei, and neither reference provides such motivation.
As noted above, the chain of title for the '562 Patent is clean. The patent was acquired by OWS from Solara Optics, Inc. pursuant to an Asset Purchase Agreement dated June 15, 2018, for a total purchase price of $34.5 million covering 12 patents. The assignment was properly recorded at the USPTO. The '562 Patent and the '847 Patent share a common patent family through a continuation relationship, which strengthens OWS's position by demonstrating a consistent technological vision across the portfolio.
Overall probability that the '562 Patent survives all invalidity challenges: 85–90%.
'015 Patent (Polarization-Diverse Grating Coupler). In addition to the prior-art references cited in the Invalidity Contentions, Lumicore asserts a prior-conception defense based on internal design documents dated 2016–2017 that allegedly show that Lumicore engineers independently conceived of a polarization-diverse grating coupler before OWS's priority date. The '015 Patent claims priority from Provisional Application No. 62/499,117, filed April 7, 2017, and was filed as a non-provisional application on August 30, 2019, issuing on August 2, 2022.
C&H's assessment is that Lumicore's prior-conception defense faces significant evidentiary hurdles. Under the corroboration requirements established in Mahurkar v. C.R. Bard, Inc., 79 F.3d 1572 (Fed. Cir. 1996), and its progeny, a party asserting prior conception must establish that the alleged conception was complete, definite, and permanent, and that it was corroborated by evidence independent of the inventor's own testimony. Lumicore's internal design documents, as identified in its Invalidity Contentions, consist primarily of internal engineering memos and CAD files. The dating of these documents is contested — OWS's forensic analysis indicates that the metadata associated with several of the key documents is unreliable, and the documents lack third-party corroboration sufficient to satisfy the Mahurkar standard. Additionally, even if Lumicore can establish prior conception in 2016, it must also demonstrate diligence from just before OWS's priority date (April 7, 2017) through to reduction to practice, and the record to date does not support such a showing.
Overall probability that the '015 Patent survives all invalidity challenges: 75–80%.
2. Overall Validity Probability
Taking into account all invalidity defenses across all four asserted patents, C&H assesses the overall validity probabilities as follows:
•  Probability that at least one asserted patent survives all invalidity challenges: approximately 85%.
•  Probability that all four patents survive: approximately 55–60%.
These probabilities are incorporated into the decision-tree analysis in Section IV.D below.
3. Inequitable Conduct / Unenforceability
Lumicore's first counterclaim alleges that the '193 Patent is unenforceable due to inequitable conduct during prosecution. Specifically, Lumicore alleges that Dr. Jian-Wei Huang, the named inventor of the '193 Patent and OWS's Chief Technology Officer, failed to disclose a prior publication — specifically, a 2015 conference paper co-authored by Dr. Huang and a former colleague — during the prosecution of the '193 Patent. Lumicore contends that this omission was material and was made with the specific intent to deceive the USPTO.
C&H's assessment is that this defense has a very low probability of success. Under the heightened standard established in Brightmoor & Co., Inc. v. Becton, Dickinson & Co., 649 F.3d 1276 (Fed. Cir. 2011) (en banc), Lumicore must prove both materiality and specific intent to deceive by clear and convincing evidence, and the court must weigh the evidence of materiality and intent together to determine whether inequitable conduct has been established. Here, the undisclosed reference was cumulative of prior art that was already before the examiner during prosecution — specifically, the examiner independently cited three references that disclose substantially the same subject matter as the undisclosed conference paper. Under Brightmoor & Co., a reference that is cumulative of art already considered by the examiner is not "but-for material" unless it is so different from the considered art that it would have changed the outcome of prosecution. There is no basis for such a finding here.
Moreover, establishing the specific-intent element requires evidence that the omission was made with the deliberate purpose of deceiving the USPTO, as opposed to mere negligence, oversight, or a good-faith judgment that the reference was not material. Dr. Huang has stated, and his prosecution counsel has confirmed, that the reference was not cited because it was considered cumulative of art already of record, and there is no evidence of any deliberate concealment.
Probability that Lumicore's inequitable conduct defense succeeds: less than 10%.
C. Willful Infringement
OWS has asserted that Lumicore's infringement of all four asserted patents was willful, entitling OWS to enhanced damages under 35 U.S.C. § 284. The standard for willful infringement, as articulated by the Supreme Court in Halo Electronics, Inc. v. Pulse Electronics, Inc., 579 U.S. 93 (2016), requires a showing of subjective willfulness — that is, that the infringer acted despite an objectively high likelihood that its conduct constituted infringement of a valid patent, and that this risk was either known or so obvious that it should have been known. Enhanced damages are reserved for "egregious" cases of infringement, and the decision to enhance is committed to the district court's discretion.
The evidence supporting OWS's willfulness theory is substantial and has continued to strengthen as discovery has progressed. The key evidence includes:
(1) FairPoint Notice Letter (January 15, 2023). Angela Reeves, Managing Director of FairPoint Licensing Group (OWS's exclusive licensing agent), sent a detailed letter to Raymond Bautista, General Counsel of Lumicore, identifying the '847, '193, and '562 Patents and their application to Lumicore's LumiLink 400G-ZR+ product. The letter included claim charts mapping specific claims to specific product features and invited Lumicore to enter into licensing negotiations.
(2) Supplemental FairPoint Notice Letter (May 15, 2023). FairPoint sent a second letter to Bautista adding the '015 Patent and identifying the LumiLink 800G-DR8 as an additional accused product.
(3) In-Person Meeting (April 20, 2023). Angela Reeves and Rebecca Tanaka met with Raymond Bautista and Kate Rourke (Lumicore's outside counsel) in Austin, Texas, to discuss the licensing opportunity. According to Reeves's deposition testimony, Lumicore "showed no interest in negotiating" and "dismissed the patents as not relevant to their products" without providing any substantive technical analysis to support that position.
(4) Post-Notice Product Launch (Q4 2023). After receiving both FairPoint notice letters and participating in the April 2023 meeting, Lumicore proceeded to launch the LumiEdge 1600G-LR product in Q4 2023 without conducting any formal design-around analysis, as confirmed by Raymond Bautista during his deposition.
(5) Refusal to Produce Opinion Letters. Lumicore's July 10, 2023 declination letter to FairPoint referenced "competent legal opinions" but Lumicore has refused to produce these opinions, asserting privilege. As discussed in Section II.B above, OWS's Motion to Compel is pending. If Lumicore continues to withhold the opinions while simultaneously relying on their existence as a defense, the jury may draw adverse inferences.
(6) Melissa Chen's Anticipated Testimony. Based on document discovery and preliminary witness interviews, former Lumicore engineer Melissa Chen is expected to testify that Lumicore's engineering team reviewed OWS's published patent application No. 2018/0123456 (corresponding to the '193 Patent) during the LumiLink 400G-ZR+ design phase in 2021–2022 — i.e., before any formal notice from OWS or FairPoint.
(7) Dr. Sandra Michaud Deposition. Lumicore's CTO admitted during her deposition that she personally reviewed OWS's published patent application during the design phase of the accused products. She denied knowledge of the issued patents until receipt of the FairPoint letter, but her admission of awareness of the published application is significant because the published claims were substantially identical to the claims that ultimately issued.
(8) Raymond Bautista Deposition. Lumicore's General Counsel confirmed receipt of the January 15, 2023 FairPoint notice letter, stated that he forwarded it to outside counsel within three business days, but admitted that no formal design-around analysis was commissioned before the launch of the LumiEdge 1600G-LR in Q4 2023.
Applying the Read factors — which include the deliberateness of the infringement, the infringer's behavior during the litigation, the infringer's size and financial condition, the closeness of the case, the duration of misconduct, and the infringer's remedial actions — the majority of factors favor OWS. The evidence strongly suggests deliberate copying or, at minimum, deliberate indifference to OWS's patent rights. Lumicore conducted no good-faith investigation before continuing infringement and launching new infringing products. The financial disparity favors OWS as a practicing entity competing directly with Lumicore, and the duration of the misconduct extends from at least Q3 2022 (the earliest date of accused-product sales) through the present.
C&H's assessment is that the probability of obtaining a willfulness finding is 55–60%. If willfulness is found, the enhancement range is likely 1.5× to 2× on post-notice lost profits, which we calculate at approximately $109.2 million in base damages for the post-notice period (January 15, 2023 through projected trial date). Treble damages (3× enhancement) are unlikely because Lumicore did apparently obtain some form of legal opinion (even though the opinions have not been produced), and the court may credit the existence of legal advice as mitigating against the most egregious characterization of Lumicore's conduct.
IV. ASSESSMENT OF DAMAGES
A. Theory 1: Lost Profits — Panduit Analysis
Under Panduit Corp. v. Stahlin Bros. Fibre Works, Inc., 575 F.2d 1152 (6th Cir. 1978), a patentee may recover lost profits upon demonstrating: (1) demand for the patented product; (2) absence of acceptable non-infringing substitutes; (3) manufacturing and marketing capability to exploit the demand; and (4) the amount of profit that would have been made. C&H has engaged Dr. Lawrence Keating of Meridian Economic Consulting Group, LLC to prepare a preliminary damages analysis under the Panduit framework, the results of which are summarized below.
Demand for the Patented Product. OWS's fiscal year 2023 revenue was $487.3 million, of which approximately $310 million was attributable to products practicing the asserted patents — specifically, the OWS-400ZR, OWS-800XR, and OWS-1600DR product families. These products compete directly with Lumicore's accused products in the market for high-bandwidth coherent optical transceivers used in hyperscale data-center interconnects and telecommunications applications. The market for 400G, 800G, and emerging 1600G optical transceiver modules has grown at a compound annual growth rate of approximately 28% from 2021 to 2024, driven by the explosive growth in data-center traffic, AI workloads, and cloud computing demand. This strong and growing demand supports the first Panduit factor.
Absence of Acceptable Non-Infringing Substitutes. Dr. Keating's analysis examined four potential alternative products in the market: (a) the Coreline Technologies CT-400 transceiver; (b) the Stratos Photonics SP-800E module; (c) the ArcLight Systems AL-400ZR module; and (d) the Prisma Semiconductor PX-800 transceiver. Each of these alternatives was evaluated against the patented features — the waveguide multiplexer architecture, the coherent transceiver integration, the micro-channel thermal management system, and the polarization-diverse grating coupler — and each was found to lack one or more of the key patented features. Specifically:
•  The Coreline CT-400 uses an older planar lightwave circuit (PLC) multiplexer technology rather than the advanced waveguide multiplexer claimed in the '847 Patent, resulting in significantly higher insertion losses and lower performance.
•  The Stratos SP-800E employs a discrete (non-integrated) coherent receiver architecture rather than the integrated silicon photonic engine claimed in the '193 Patent, resulting in a larger form factor and higher power consumption.
•  The ArcLight AL-400ZR lacks the micro-channel thermal management system claimed in the '562 Patent, relying instead on conventional thermal-interface-material (TIM) approaches with inferior thermal performance.
•  The Prisma PX-800 does not incorporate a polarization-diverse grating coupler, instead using edge-coupled fiber attachment, which limits its applicability in certain high-density deployment scenarios.
While these products are competitors in the broad transceiver market, they do not constitute "acceptable non-infringing substitutes" within the meaning of Panduit because they lack the specific patented features that drive customer demand for the OWS and Lumicore product lines. The second Panduit factor is satisfied.
Manufacturing and Marketing Capability. OWS has the manufacturing and marketing capability to serve the demand that was captured by Lumicore's accused products. OWS maintains manufacturing relationships with two foundry partners — a leading silicon photonics foundry in Singapore and a packaging facility in Malaysia — that have the capacity to scale production to meet additional demand. OWS has approximately 1,250 employees, including a global sales force covering all major markets, and has been approved as a qualified vendor by the majority of the hyperscale data-center operators that purchase Lumicore's accused products. The third Panduit factor is satisfied.
Profit Calculation. OWS's gross margin on the competing product families (OWS-400ZR, OWS-800XR, OWS-1600DR) is 47.3%, as confirmed by OWS's audited financial statements and verified by Dr. Keating's analysis of OWS's cost-accounting data. Applying this margin to the displaced revenue yields the lost-profit damages figure.
Market-Share Displacement. Dr. Keating's preliminary analysis estimates that OWS would have captured 38.2% of Lumicore's accused-product sales in a "but-for" world in which Lumicore's products were removed from the market. This market-share displacement figure is derived from an analysis of customer overlap data showing that OWS and Lumicore compete head-to-head at 12 of the 20 largest hyperscale data-center operators, adjusted downward for the 8 customers where OWS is not currently an approved vendor or where other competitive factors would have directed the sales to third-party alternatives. The 38.2% figure reflects a conservative application of the Panduit methodology, recognizing that not all diverted sales would have gone to OWS.
Projected Accused-Product Revenue. Based on Lumicore's financial data produced in discovery (under AEO designation), Dr. Keating projects total accused-product revenue from Q3 2022 (the earliest date of accused-product sales) through Q4 2025 (projected trial date) to be approximately $714.6 million. This projection is based on historical sales data through Q2 2024 and forecasted growth rates consistent with Lumicore's publicly disclosed guidance and industry analyst estimates.
Lost-Profit Damages Calculation:
$714.6M (accused-product revenue) × 38.2% (market-share displacement) × 47.3% (OWS gross margin) = approximately $128.9 million
Key Vulnerabilities. Lumicore's damages expert, Dr. Natasha Volkov of Pinnacle Analytics Partners LLP, will likely challenge the 38.2% market-share displacement figure, arguing that additional non-infringing alternatives exist in the market and that OWS's share of the diverted sales would be lower. Dr. Volkov may also challenge OWS's gross margin figure by arguing that incremental production costs would be higher than the average margin, and that OWS would have needed to offer competitive pricing concessions to win the displaced sales. C&H estimates that if Lumicore's challenges are partially successful, the lost-profit figure could be reduced by 20–25%. However, we are confident that the core methodology is sound and that Dr. Keating's analysis will withstand Daubert scrutiny.
Probability-Adjusted Lost Profits: $128.9M × 80% (probability of establishing all Panduit factors at trial) = approximately $103.1 million.
B. Theory 2: Reasonable Royalty — Georgia-Pacific Analysis
For sales where lost profits cannot be established — specifically, sales to customers that OWS could not have served because OWS was not an approved vendor or did not have the capacity to serve those customers — OWS seeks a reasonable royalty under 35 U.S.C. § 284. Dr. Keating has prepared a preliminary reasonable royalty analysis based on the fifteen-factor framework established in Georgia-Pacific Corp. v. U.S. Plywood Corp., 318 F. Supp. 1116 (S.D.N.Y. 1970).
Non-Lost-Profit Accused-Product Revenue. The revenue attributable to the reasonable-royalty theory is the portion of accused-product sales that would not have been captured by OWS in the but-for world:
$714.6M − ($714.6M × 38.2%) = approximately $441.6 million
Hypothetical Negotiation Date. Under the Georgia-Pacific framework, the reasonable royalty is determined based on a hypothetical negotiation between a willing licensor and a willing licensee at the time infringement began. C&H proposes a hypothetical negotiation date of Q2 2022, immediately before the launch of the LumiLink 400G-ZR+.
Proposed Royalty Rate. Dr. Keating's analysis supports a royalty rate of 8.5%, based on an analysis of five comparable license agreements:
The industry range for patent royalties on photonic transceiver technology is approximately 4.0%–12.5%, with the precise rate depending on the scope of the licensed technology, the strength of the patents, the number of patents licensed, and the competitive relationship between the parties. Dr. Keating's proposed rate of 8.5% falls near the center of the comparable agreements and is consistent with the OWS–Helix agreement, which involved similar patent scope and product overlap.
Reasonable Royalty Calculation:
$441.6M × 8.5% = approximately $37.5 million
Key Vulnerabilities. Lumicore's damages expert is expected to challenge the royalty base, arguing that the entire market value rule ("EMVR") is improperly applied to the module-level price and that the royalty base should instead be limited to the smallest salable patent-practicing unit ("SSPPU") — i.e., the individual photonic integrated circuit die rather than the complete transceiver module. If the SSPPU approach is adopted, the royalty base could be reduced by 40–60%, though a higher royalty rate on the smaller base may partially offset this reduction. Dr. Volkov may also propose a lower comparable rate in the 2–4% range based on agreements that are less directly comparable.
C&H and Dr. Keating have prepared a detailed apportionment analysis demonstrating that the patented features — the waveguide multiplexer, the thermal management micro-channels, and the polarization-diverse grating coupler — are the primary drivers of customer demand for the accused transceiver modules. Customer survey data, competitive win/loss analyses, and Lumicore's own marketing materials all support the conclusion that these features are essential to the product's commercial value and that the EMVR is properly applied to the module-level price. This analysis has been upheld in similar cases in the Eastern District of Texas.
Probability-Adjusted Reasonable Royalty: $37.5M × 75% (probability of establishing the royalty rate and base at trial) = approximately $28.1 million.
C. Theory 3: Enhanced Damages for Willful Infringement
As discussed in Section III.C above, OWS seeks enhanced damages under 35 U.S.C. § 284 based on Lumicore's willful infringement. Enhanced damages are calculated on the post-notice damages base — that is, the lost profits attributable to Lumicore's accused-product sales occurring after the January 15, 2023 FairPoint notice letter.
Post-Notice Lost Profits. Based on Dr. Keating's analysis, post-notice accused-product revenue (January 15, 2023 through projected trial date of February 2, 2026) is approximately $590 million, yielding post-notice lost profits of approximately $590M × 38.2% × 47.3% = approximately $109.2 million.
Enhancement Sought. OWS will seek a 2× multiplier on the post-notice lost-profit component, yielding enhanced damages of approximately $109.2 million additional (i.e., an additional amount equal to the post-notice lost profits, for a total of 2× the base post-notice lost profits).
It should be noted that the total complaint demand of approximately $210 million is a blended, rounded figure that incorporates scenarios from all three damages theories and does not represent the arithmetic maximum of all theories applied simultaneously. The theoretical maximum under a full-sweep scenario (all four patents, full lost profits, full royalty, and 2× enhancement) would be approximately $275.6 million, but such an outcome requires prevailing on every issue, which is improbable.
Probability-Adjusted Enhanced Damages: $109.2M × 55% (probability of willfulness finding) × 60% (probability that court exercises discretion to enhance at 2× level) = approximately $36.0 million.
D. Risk-Adjusted Expected Value — Decision-Tree Analysis
C&H has constructed a comprehensive decision-tree model to calculate the risk-adjusted expected value of the case. The model incorporates the following probability nodes and weighted outcomes:
Decision-Tree Node Probabilities
Node 1 — Prevail on Liability (at least one patent, at least one accused product): 75%. This node captures the probability that OWS will establish infringement of at least one asserted patent by at least one accused product, taking into account claim construction risk, evidentiary uncertainties, and jury unpredictability.
Node 2 — Survive Invalidity Challenge (at least one asserted patent): 85%. This node captures the probability that Lumicore's invalidity defenses will fail with respect to at least one patent, such that the liability finding is not nullified by a validity defense.
Node 3 — Combined Liability Probability: Node 1 × Node 2 = 75% × 85% = 63.75%. This represents the probability that OWS obtains a favorable verdict on at least one patent and the infringed patent is not found invalid.
Node 4 — Damages Scenarios if OWS Prevails:
Under the assumption that OWS prevails on liability (i.e., conditional on passing through Nodes 1 and 2), the following damages scenarios are modeled:
(a) Best Case (35% probability conditional on liability win): OWS prevails on all four patents, establishes full lost-profit damages, obtains a reasonable royalty on the non-lost-profit sales, and the court enhances damages at 2× for willful infringement. Damages in this scenario: $128.9M (lost profits) + $37.5M (reasonable royalty) + $109.2M (enhanced damages) = $275.6 million. Weighted contribution: $275.6M × 35% = $96.5M.
(b) Expected Case (45% probability conditional on liability win): OWS prevails on two to three patents, establishes most of the lost-profit claim (but with some market-share displacement reduction), obtains a reasonable royalty on the remainder, and the court partially enhances damages (e.g., 1.5× on a portion of post-notice damages). Damages in this scenario: approximately $166.4 million. Weighted contribution: $166.4M × 45% = $74.9M.
(c) Conservative Case (20% probability conditional on liability win): OWS prevails on one to two patents, with reduced lost profits due to successful challenges to market-share displacement, royalty-only damages on the remainder, and no enhancement. Damages in this scenario: approximately $90 million. Weighted contribution: $90M × 20% = $18.0M.
Weighted Average Damages if Liability Established: $96.5M + $74.9M + $18.0M = approximately $189.4 million.
Node 5 — Expected Value Calculation:
Weighted average damages × combined liability probability = $189.4M × 63.75% = approximately $120.7 million (monetary damages component).
Adding the present value of injunctive relief (quantified at approximately $17–$20 million based on the analysis in Section IV.E below):
Total Risk-Adjusted Expected Value: approximately $138 million (rounded).
A detailed decision-tree diagram with all probability nodes and weighted outcomes is attached as Exhibit A.
E. Value of Injunctive Relief
In addition to monetary damages, OWS has sought a permanent injunction against Lumicore's continued manufacture, use, sale, offer for sale, and importation of the accused products. The value of injunctive relief to OWS extends beyond its immediate economic impact and serves as a critical source of settlement leverage.
Impact on Lumicore. If a permanent injunction is granted, Lumicore would be required to cease all sales of the LumiLink 400G-ZR+, LumiLink 800G-DR8, and LumiEdge 1600G-LR product lines. Based on Lumicore's FY 2023 revenue data:
•  LumiLink 400G-ZR+: $94.8 million (FY